title: Armodafinil.
abstract: Armodafinil is the R-enantiomer of modafinil, a wake-promoting agent, that primarily affects areas of the brain involved in controlling wakefulness. Once-daily armodafinil was effective in improving wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome (OSA) [despite treatment of the underlying condition], narcolepsy or shift work sleep disorder (SWSD) in four large (n > 195), double-blind, multinational trials of 12 weeks' duration. Compared with placebo, mean sleep latency (coprimary endpoint) was significantly improved with armodafinil 150 or 250 mg once daily in patients with OSA or narcolepsy, and with armodafinil 150 mg once daily in patients with SWSD, as assessed by the Multiple Sleep Latency Test (MSLT) or the Maintenance of Wakefulness Test (MWT). Furthermore, a significantly higher proportion of armodafinil than placebo recipients achieved a response (at least a minimal improvement) on the Clinical Global Impressions of Change (CGI-C) scale at study end in these four trials (coprimary endpoint). Once-daily armodafinil was generally well tolerated in adult patients with excessive sleepiness associated with OSA (despite treatment of the underlying condition), narcolepsy or SWSD.
authors.affiliation: Wolters Kluwer Health, Adis, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand. demail@adis.co.nz
authors.forename: Karly P
authors.initials: KP
authors.lastname: Garnock-Jones
authors.forename: Sohita
authors.initials: S
authors.lastname: Dhillon
authors.forename: Lesley J
authors.initials: LJ
authors.lastname: Scott
mesh_terms: D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D000077408:Modafinil; D009290:Narcolepsy / Q000188:drug therapy; D020181:Sleep Apnea, Obstructive / Q000188:drug therapy; D020178:Sleep Disorders, Circadian Rhythm / Q000188:drug therapy; D013237:Stereoisomerism; D014851:Wakefulness / Q000187:drug effects*
chemical_list: D001559:Benzhydryl Compounds; D000697:Central Nervous System Stimulants; D000077408:Modafinil
references.citation: Drugs Today (Barc). 2008 Jun;44(6):395-414
references.pmid: 18596995
references.citation: Respir Med. 2007 Mar;101(3):616-27
references.pmid: 16908126
references.citation: CNS Drugs. 2005;19(9):785-803
references.pmid: 16142993
references.citation: Curr Med Res Opin. 2006 Apr;22(4):761-74
references.pmid: 16684437
references.citation: J Occup Environ Med. 2004 Oct;46(10):1010-2
references.pmid: 15602174
references.citation: Clin Pharmacokinet. 2008;47(1):61-74
references.pmid: 18076219
references.citation: J Clin Pharmacol. 1999 Jan;39(1):30-40
references.pmid: 9987698
references.citation: Pharmacol Biochem Behav. 2009 May;92(3):549-57
references.pmid: 19249327
references.citation: Clin Drug Investig. 2009;29(2):87-100
references.pmid: 19133704
references.citation: Clin Ther. 2006 May;28(5):689-706
references.pmid: 16861091
references.citation: Drug Ther Bull. 2004 Jul;42(7):52-6
references.pmid: 15270072
references.citation: Curr Med Res Opin. 2006 Jan;22(1):159-67
references.pmid: 16393442
references.citation: Clin Pharmacokinet. 2003;42(2):123-37
references.pmid: 12537513
references.citation: Ann Clin Psychiatry. 2004 Apr-Jun;16(2):101-9
references.pmid: 15328903
references.citation: J Clin Pharmacol. 1999 Mar;39(3):281-8
references.pmid: 10073328